Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

摘要: Background and Objectives Trisomy 8 (+8) is among the commonest genetic aberrations seen in acute myeloid leukemia (AML). However, prognostic significance of this aberration best consolidation strategy for patients with it are still not resolved. Additional indicators needed to further classify these determine their appropriate management. Design Methods Individual patient data-based meta-analysis was performed on 131 (median age 50 (18–60) years) +8 as a sole or one additional treated between 1993 2002 eight prospective German AML treatment trials. All received state-of-the-art including high-dose cytarabine option autologous allogeneic hematopoietic stem cell transplantation (HSCT). Results In total, had 3-year overall survival (OS) 29% relapse-free (RFS) 32%. Independent factors contributing shorter OS were ≥45 years, extramedullary disease, percentage positive metaphases ≥80%. Combining three variables established hierarchical model OS. The 13% high-risk group, 36% intermediate-risk 55% low-risk group ( p <0.0001). Age <45 years HSCT (as treated) independent longer RFS. cytogenetic other than t(8;21), inv(16), t(16;16), t(15;17) 11q23 no influence outcome. Interpretation Conclusions We provide new risk stratification +8. data indicate that may prolong RFS compared achieved strategies post-remission therapy.